These agents show only limited activity as single agents in the treatment of HER2-overexpressing breast cancer, despite a preponderance of experimental evidence suggesting that these cancers are highly dependent on HER2 function (Burstein et al, 2004; and reviewed in Moasser, 2007b). The gene discussed is ERBB2; the disease is cancer.